PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity

PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kδ modulate the tumor immune microenvironment of pre-clinical mouse...

Descripción completa

Detalles Bibliográficos
Autores principales: Carnevalli, Larissa S., Sinclair, Charles, Taylor, Molly A., Gutierrez, Pablo Morentin, Langdon, Sophie, Coenen-Stass, Anna M. L., Mooney, Lorraine, Hughes, Adina, Jarvis, Laura, Staniszewska, Anna, Crafter, Claire, Sidders, Ben, Hardaker, Elizabeth, Hudson, Kevin, Barry, Simon T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307194/
https://www.ncbi.nlm.nih.gov/pubmed/30587236
http://dx.doi.org/10.1186/s40425-018-0457-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307194/
https://www.ncbi.nlm.nih.gov/pubmed/30587236
http://dx.doi.org/10.1186/s40425-018-0457-0

Ejemplares similares